Table 1 Characteristics of five inception cohorts of HAART initiators (2008–2012)
Variable | 2008 (%) N = 836 | 2009 (%) N = 810 | 2010 (%) N = 804 | 2011 (%) N = 753 | 2012 (%) N = 730 | p-value |
|---|---|---|---|---|---|---|
WHO stage | ||||||
I | 11 (1.3) | 18 (2.2) | 108 (13.5) | 110 (14.6) | 155 (21.2) | <0.0001 |
II | 164 (19.6) | 66 (8.2) | 133 (16.6) | 148 (19.7) | 150 (20.6) | |
III | 105 (12.7) | 50 (7.4) | 221 (27.5) | 343 (45.5) | 313 (42.9) | |
IV | 71 (8.5) | 52 (6.4) | 123 (15.3) | 143 (19.0) | 102 (14.0) | |
Missing | 485 (57.9) | 614 (65.8) | 218 (27.1) | 9 (1.2) | 10 (1.4) | |
Age group | ||||||
≤ 25 years | 37 (4.4) | 37 (4.6) | 35 (4.4) | 45 (6.0) | 45 (6.2) | 0.0990 |
26–35 | 253 (30.3) | 247 (30.5) | 218 (27.1) | 205 (27.2) | 189 (25.9) | |
36–45 | 265 (31.7) | 258 (31.8) | 255 (31.8) | 246 (32.7) | 227 (31.1) | |
46–55 | 154 (18.4) | 130 (16.0) | 148 (18.4) | 131 (17.4) | 145 (19.9) | |
56–65 | 37 (4.4) | 29 (3.6) | 48 (6.0) | 30 (4.0) | 48 (6.6) | |
> 65 | 90 (10.8) | 109 (13.5) | 99 (12.3) | 96 (12.8) | 76 (10.4) | |
Gender | ||||||
Male | 290 (34.7) | 301 (37.2) | 289 (36.0) | 252 (33.5) | 241 (33.0) | 0.3995 |
Female | 546 (65.3) | 509 (62.8) | 515 (64.0) | 501 (66.5) | 489 (70.0) | |
Initial treatment | ||||||
AZT/3TC/EFV | 331 (39.6) | 263 (32.5) | 271 (33.7) | 286 (38.0) 147 | 317 (42.4) | <0.0001 |
AZT/3TC/NVP | 238 (28.5) | 193 (23.8) | 166 (20.7) | (19.5) | 154 (21.1) | |
d4T/3TC/EFV | 154 (18.4) | 208 (25.7) | 239 (29.7) | 117 (15.5) | 0 (0) | |
d4T/3TC/NVP | 101 (12.1) | 137 (16.9) | 103 (12.8) | 58 (7.7) | 0 (0) | |
TDF/3TC/EFV | 3 (0.4) | 2 (0.3) | 7 (0.9) | 100 (13.3) | 202 (27.7) | |
TDF/3TC/NVP | 0 | 1 (0.1) | 3 (0.4) | 26 (3.5) | 41 (5.6) | |
OTHER | 9 (1.1) | 6 (0.7) | 15 (1.9) | 19 (2.5) | 16 (2.2) | |
Recorded death | ||||||
32 (3.8) | 65 (8.0) | 52 (6.5) | 44 (5.8) | 44 (6.0) | – | |
Number of treatment changes | ( N = 234) | ( N = 240) | ( N = 280) | ( N = 171) | ( N = 35) | |
AZT/3TC/EFV | 41 (17.5) | 19 (7.9) | 21 (7.5) | 20 (11.7) | 16 (45.7) | <0.0001 |
AZT/3TC/NVP | 26 (11.1) | 23 (9.6) | 13 (4.6) | 15 (8.8) | 13 (37.1) | |
d4T/3TC/EFV | 98 (41.9) | 118 (49.2) | 158 (56.6) | 87 (50.9) | 0 | |
d4T/3TC/NVP | 66 (28.2) | 80 (33.3) | 84 (29.9) | 40 (23.4) | 0 | |
TDF/3TC/EFV | 1 (0.4) | 0 | 1 (0.4) | 1 (0.6) | 2 (5.7) | |
TDF/3TC/NVP | 0 | 0 | 0 | 1 (0.6) | 2 (5.7) | |
OTHER | 2 (0.9) | 0 | 3 (1.1) | 7 (4.1) | 2 (5.7) | |
Log-rank test for treatment type | ||||||
<0.0001 | <0.0001 | <0.0001 | <0.0001 | 0.012 |